European PRAC warning of Guillain-Barre syndrome with Vaxzevria (AstraZeneca) Covid-19 vaccine
The PRAC has recommended a change to the product information to include a warning to raise awareness among healthcare professionals and people taking the vaccine of cases of Guillain-Barre syndrome (GBS) reported following vaccination.
Source:
European Medicines Agency
SPS commentary:
Healthcare professionals should be alert to signs and symptom of GBS, allowing early diagnosis, supportive care and treatment. People taking the vaccine are advised to seek immediate medical attention if they develop weakness and paralysis in the extremities that can progress to the chest and face. The benefit-risk balance of the vaccine remains unchanged.